Takeda Pharmaceutical Company Limited
TAK · NYSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $4,582 | $4,264 | $4,027 | $3,569 |
| % Growth | 7.5% | 5.9% | 12.8% | – |
| Cost of Goods Sold | $1,580 | $1,432 | $1,244 | $1,107 |
| Gross Profit | $3,001 | $2,832 | $2,783 | $2,462 |
| % Margin | 65.5% | 66.4% | 69.1% | 69% |
| R&D Expenses | $730 | $730 | $633 | $526 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,105 | $1,054 | $997 | $886 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $824 | $834 | $662 | $589 |
| Operating Expenses | $2,659 | $2,618 | $2,293 | $2,001 |
| Operating Income | $343 | $214 | $491 | $461 |
| % Margin | 7.5% | 5% | 12.2% | 12.9% |
| Other Income/Exp. Net | -$168 | -$161 | -$115 | -$158 |
| Pre-Tax Income | $175 | $53 | $375 | $303 |
| Tax Expense | $67 | -$91 | $58 | $72 |
| Net Income | $108 | $144 | $317 | $230 |
| % Margin | 2.4% | 3.4% | 7.9% | 6.4% |
| EPS | 34.17 | 46.05 | 102.15 | 73.57 |
| % Growth | -25.8% | -54.9% | 38.8% | – |
| EPS Diluted | 33.62 | 45.58 | 100.97 | 72.94 |
| Weighted Avg Shares Out | 3 | 3 | 3 | 3 |
| Weighted Avg Shares Out Dil | 3 | 3 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $20 | $0 | $6 | $5 |
| Interest Expense | $137 | $1 | $117 | $122 |
| Depreciation & Amortization | $761 | $644 | $664 | $583 |
| EBITDA | $1,211 | $1,144 | $1,284 | $1,183 |
| % Margin | 26.4% | 26.8% | 31.9% | 33.2% |